Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).

医学 拉帕蒂尼 帕妥珠单抗 曲妥珠单抗 内科学 紫杉烷 紫杉醇 养生 肿瘤科 乳腺癌 不利影响 新辅助治疗 卡培他滨 胃肠病学 癌症 结直肠癌
作者
Tejal Patel,Joe Ensor,Sarah L. Creamer,Angel Rodriguez,Polly Niravath,Jorge Darcourt,Virginia Kaklamani,Jane Meisel,Xiaoxian Li,John G. Kuhn,Roberto R. Rosato,Anna Belcheva,Toniva Boone,Jenny Chee Ning Chang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): 581-581 被引量:1
标识
DOI:10.1200/jco.2018.36.15_suppl.581
摘要

581 Background: Based on data from our phase I study of trastuzumab-emtansine (T-DM1), Lapatinib (L) and Nab Paclitaxel (Nab-P), a multicenter randomized open label phase II neoadjuvant study was conducted comparing this regimen to the standard of care (SOC) Paclitaxel (Pac), Trastuzumab (T), and Pertuzumab (P) in patients with HER2 over-expressed breast cancer. Methods: Patients in the experimental arm received T-DM1 3.0 mg/kg Q3W, L 750mg oral daily and Nab-P 80 mg/m2 weekly (QW) X 12 weeks. Patients in SOC arm received Pac 80mg/m2 QW, T 2mg/kg QW, and P 420mg Q3W X 12 weeks. The primary objective was to evaluate the proportion of patients with residual cancer burden (RCB) 0 or 1. Key secondary objectives included correlative assessments of PIK3CA mutations, PTEN expression, and HER2 subtypes, all of which are ongoing. Results: Thirty of the 33 enrolled patients were evaluable. Patient demographics were.The proportion of patients with RCB 0 & I was significantly higher in the T-DM1, L and Nab-P arm than in the SOC arm (100% vs. 62.5%, p 0.0035). Importantly, the RCB 0 & 1 in the ER positive subset of patients was 100% compared with 25% in SOC (p 0.0035). Common adverse events included elevated liver function tests, fatigue, diarrhea and neuropathy. Conclusions: TDM1 plus L and Nab-P therapy was well tolerated with noteworthy responses in all patients, and especially in the ER positive subset, a group which has historically had lower response rates to neoadjuvant anti-HER2-directed therapy. Further evaluation of this regimen is warranted. Clinical trial information: NCT02073487.Efficacy. Experimental SOC P-value RCB 0 - and I 14 (100) 10 (62.5) 0.0035 ER Negative 6 (100) 8 (100) ER Positive 8 (100) 2 (25) RCB II and III 0 6 (37.50)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晨烨完成签到,获得积分10
刚刚
阿申爱乐的应助被皮卡丘采纳,获得30
刚刚
苏苏苏完成签到,获得积分10
1秒前
茶兔的应助被初景采纳,获得10
1秒前
YY完成签到,获得积分10
1秒前
biu发布了新的文献求助10
2秒前
章文荣发布了新的文献求助10
2秒前
微笑的白柏完成签到,获得积分10
2秒前
3秒前
小二郎的应助被学术饕餮采纳,获得10
3秒前
rise完成签到,获得积分10
3秒前
苏苏苏发布了新的文献求助10
3秒前
4秒前
4秒前
5秒前
orixero的应助被昕昕233采纳,获得10
5秒前
6秒前
嘻嘻哈哈的应助被nicoleJ采纳,获得10
6秒前
7秒前
7秒前
8秒前
ili完成签到,获得积分10
8秒前
8秒前
dOing完成签到,获得积分10
8秒前
思源的应助被奋斗小真采纳,获得10
9秒前
superlative完成签到,获得积分10
10秒前
科研通AI6.2的应助被比巴卜采纳,获得10
10秒前
SunnyLife发布了新的文献求助10
10秒前
章文荣完成签到,获得积分10
10秒前
12秒前
LXL发布了新的文献求助10
12秒前
snail完成签到,获得积分10
12秒前
yu完成签到,获得积分10
12秒前
CipherSage的应助被橘色的嘟嘟采纳,获得10
13秒前
13秒前
13秒前
科研小丧彪完成签到,获得积分10
13秒前
仙女的小可爱完成签到 ,获得积分10
13秒前
13秒前
ljx完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187612
求助须知:如何正确求助?哪些是违规求助? 9575734
关于积分的说明 21842594
捐赠科研通 7785476
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559478
邀请新用户注册赠送积分活动 2481952